Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Receivables (2016 - 2025)

OptimizeRx's Receivables history spans 16 years, with the latest figure at $35.9 million for Q3 2025.

  • For Q3 2025, Receivables rose 11.2% year-over-year to $35.9 million; the TTM value through Sep 2025 reached $35.9 million, up 11.2%, while the annual FY2024 figure was $41.5 million, 2.07% down from the prior year.
  • Receivables for Q3 2025 was $35.9 million at OptimizeRx, down from $37.0 million in the prior quarter.
  • Across five years, Receivables topped out at $42.3 million in Q4 2023 and bottomed at $1.2 million in Q2 2021.
  • The 5-year median for Receivables is $18.7 million (2022), against an average of $19.7 million.
  • The largest annual shift saw Receivables tumbled 88.75% in 2021 before it surged 1440.91% in 2022.
  • A 5-year view of Receivables shows it stood at $26.9 million in 2021, then dropped by 4.36% to $25.7 million in 2022, then skyrocketed by 64.46% to $42.3 million in 2023, then dropped by 2.07% to $41.5 million in 2024, then decreased by 13.28% to $35.9 million in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Receivables are $35.9 million (Q3 2025), $37.0 million (Q2 2025), and $37.0 million (Q1 2025).